Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012

Uncertainty exists around the need to include an anthracycline if taxane-based adjuvant chemotherapy is being used for human epidermal growth factor receptor-2 (HER2) negative and axillary lymph node negative (LNN) breast cancer. We identified all patients who were diagnosed with HER2-negative, LNN...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannouf, Malek, Batra, Atul, Lupichuk, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025747/
https://www.ncbi.nlm.nih.gov/pubmed/33806441
http://dx.doi.org/10.3390/curroncol28020109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025747/
https://www.ncbi.nlm.nih.gov/pubmed/33806441
http://dx.doi.org/10.3390/curroncol28020109

Ejemplares similares